<?xml version="1.0" encoding="UTF-8"?>
<p>No serious adverse event was reported during the treatment period and no patient stopped therapy because of adverse events. Anemia (hemoglobin &lt;10 g/dL) was reported in 2 patients receiving ribavirin and resolved after dose reduction in both cases. One patient died from progressive liver disease during the first month of treatment. No deaths or hospital admissions due to opioid overdose or other drug-related problems were reported.</p>
